Forbes May 21, 2025
Regeneron Pharmaceuticals announced on Monday it will acquire bankrupt genomics firm 23andMe for $256 million through a bankruptcy auction, promising to maintain ethical standards in handling sensitive customer DNA information.
According to Reuters, the New York-based pharmaceutical giant aims to leverage 23andMe’s extensive database of over 15 million customer DNA samples to enhance its genomic-driven drug discovery processes. The acquisition comes at a crucial time as concerns about genetic data privacy have intensified following 23andMe’s data breach in 2023 that affected millions of users.
The Bankruptcy Sale And Data Privacy Promises
23andMe, once valued at $6 billion, filed for bankruptcy in March 2025 after experiencing declining consumer interest and dealing with the fallout from its significant data breach. The company’s...
Today's Sponsors
Today's Sponsor